TW202317192A - 用於阿茲海默氏症治療的生物標記物 - Google Patents
用於阿茲海默氏症治療的生物標記物 Download PDFInfo
- Publication number
- TW202317192A TW202317192A TW111125802A TW111125802A TW202317192A TW 202317192 A TW202317192 A TW 202317192A TW 111125802 A TW111125802 A TW 111125802A TW 111125802 A TW111125802 A TW 111125802A TW 202317192 A TW202317192 A TW 202317192A
- Authority
- TW
- Taiwan
- Prior art keywords
- subject
- months
- antibody
- ratio
- therapeutically effective
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220434P | 2021-07-09 | 2021-07-09 | |
| US63/220,434 | 2021-07-09 | ||
| US202163203444P | 2021-07-22 | 2021-07-22 | |
| US63/203,444 | 2021-07-22 | ||
| US202163263255P | 2021-10-29 | 2021-10-29 | |
| US63/263,255 | 2021-10-29 | ||
| US202163263928P | 2021-11-11 | 2021-11-11 | |
| US63/263,928 | 2021-11-11 | ||
| US202163264551P | 2021-11-24 | 2021-11-24 | |
| US63/264,551 | 2021-11-24 | ||
| US202263306028P | 2022-02-02 | 2022-02-02 | |
| US63/306,028 | 2022-02-02 | ||
| US202263269372P | 2022-03-15 | 2022-03-15 | |
| US63/269,372 | 2022-03-15 | ||
| US202263364618P | 2022-05-12 | 2022-05-12 | |
| US63/364,618 | 2022-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202317192A true TW202317192A (zh) | 2023-05-01 |
Family
ID=83232761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111125802A TW202317192A (zh) | 2021-07-09 | 2022-07-08 | 用於阿茲海默氏症治療的生物標記物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250163135A1 (https=) |
| EP (1) | EP4367516A1 (https=) |
| JP (1) | JP2024525559A (https=) |
| KR (1) | KR20240033017A (https=) |
| AU (1) | AU2022307687A1 (https=) |
| CA (1) | CA3225302A1 (https=) |
| CL (1) | CL2024000063A1 (https=) |
| IL (1) | IL309468A (https=) |
| MX (1) | MX2023015183A (https=) |
| TW (1) | TW202317192A (https=) |
| WO (1) | WO2023283650A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
| WO2025019457A1 (en) * | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025260029A1 (en) | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| IL296992A (en) * | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| TWI843040B (zh) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
-
2022
- 2022-07-08 AU AU2022307687A patent/AU2022307687A1/en active Pending
- 2022-07-08 WO PCT/US2022/073576 patent/WO2023283650A1/en not_active Ceased
- 2022-07-08 EP EP22765973.7A patent/EP4367516A1/en active Pending
- 2022-07-08 CA CA3225302A patent/CA3225302A1/en active Pending
- 2022-07-08 JP JP2024500220A patent/JP2024525559A/ja active Pending
- 2022-07-08 TW TW111125802A patent/TW202317192A/zh unknown
- 2022-07-08 KR KR1020247004758A patent/KR20240033017A/ko active Pending
- 2022-07-08 IL IL309468A patent/IL309468A/en unknown
- 2022-07-08 US US18/577,174 patent/US20250163135A1/en active Pending
- 2022-07-08 MX MX2023015183A patent/MX2023015183A/es unknown
-
2024
- 2024-01-08 CL CL2024000063A patent/CL2024000063A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3225302A1 (en) | 2023-01-12 |
| JP2024525559A (ja) | 2024-07-12 |
| MX2023015183A (es) | 2024-03-14 |
| CL2024000063A1 (es) | 2024-08-02 |
| AU2022307687A1 (en) | 2024-01-04 |
| KR20240033017A (ko) | 2024-03-12 |
| EP4367516A1 (en) | 2024-05-15 |
| US20250163135A1 (en) | 2025-05-22 |
| IL309468A (en) | 2024-02-01 |
| WO2023283650A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202317192A (zh) | 用於阿茲海默氏症治療的生物標記物 | |
| JP7676556B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 | |
| TW202339794A (zh) | 使用ｐ—ｔａｕ１８１水平之治療方法 | |
| JP7792428B2 (ja) | 抗アミロイドベータ抗体及びその使用 | |
| EP3464350A1 (en) | Methods for treating alzheimer's disease | |
| TW202430554A (zh) | 使用ｔａｕ ＰＥＴ水平之治療方法 | |
| JP2024547001A (ja) | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 | |
| TW202328178A (zh) | 抗Ａβ初原纖維抗體的皮下配製物及其使用方法 | |
| CN117940773A (zh) | 用于阿尔茨海默病治疗的生物标记物 | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| WO2026075947A1 (en) | Dosing regimens for early alzheimer's disease | |
| KR20260022396A (ko) | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 | |
| EA052116B1 (ru) | Антитела к бета-амилоидному пептиду n3pglu и варианты их применения | |
| KR20260038283A (ko) | 항미생물 펩티드 |